Introduction:Basic information about CAS 320367-13-3|Lixisenatide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lixisenatide |
|---|
| CAS Number | 320367-13-3 | Molecular Weight | 4858.49000 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C215H347N61O65S | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | lixisenatide |
|---|
| Synonym | More Synonyms |
|---|
Lixisenatide BiologicalActivity
| Description | Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM). Sequence: His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys-NH2. |
|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Glucagon ReceptorResearch Areas >>Metabolic DiseasePeptides |
|---|
| Target | GLP-1 receptor[1][2]. |
|---|
| References | [1]. Ahrén B et al. Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. Diabetes Ther. 2016 Jun 18 [2]. Lorenz M, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia. Regul Pept. 2013 Aug 10;185:1-8. |
|---|
Chemical & Physical Properties
| Molecular Formula | C215H347N61O65S |
|---|
| Molecular Weight | 4858.49000 |
|---|
| Exact Mass | 4855.54000 |
|---|
| PSA | 2085.46000 |
|---|
| LogP | 2.13170 |
|---|
| InChIKey | XVVOERDUTLJJHN-UHFFFAOYSA-N |
|---|
| SMILES | CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(N)Cc1c[nH]cn1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O |
|---|
| Storage condition | -20°C |
|---|
Synonyms
| ZP 10 |
| AVE 0010 |
| ZP10A peptide |
| lixisenatide |
| des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)- peptidylpenta-L-lysyl-L-lysinamide |
| AVE0010 |
| Lyxumia |
| UNII-74O62BB01U |